Stock Market Report 2009
Focus is on companies looking to help people and not line their pockets by ripping off the American People like many Wall Street and Banking companies.
Cancer Treatments
Cel Sci Market Report CVM closed at $1.45 September 17, 2009
Lead Drug Multikine cancer immunotherapy drug designed as first line standard of care cancer treatment. Multikine is used for head and neck cancers which is the sixth most frequent occuring cancer worldwide with an estimated 600,000 new cases diagnosed each year. Company is currently working on the global launch of Phase 3 Trial for Multikine. Valadation of manufacuturing facility in Baltimore Maryland and funding is needed to begin the Phase 3 Trial. Phase 2 Results seem to be very impressive to say the least and information can be found on their website.
Cel Sci also is currently working on a treatment for patients infected with H1N1 using their L.E.A.P.S technology.
This company announced they were granted Expedited FDA Review for the treatment of H1N1. So Cel Sci will be working hand and hand with FDA.
Oct 6 Cel Sci Update Insiders of the company made recent purchases on the open market around $1.71 Sept. 30 Check Sec Filings. Also you have the street dot com putting out two garbage articles on CVM. The writer actually talks about about a guy posting on a yahoo message board in his news story. If this a news story I don't want a hear about a yahoo message board post. When it comes to trading the markets the street dot com is the essence of garbage, most recent Sec Filings you see Jim Cramer selling the stock of his own company the street, will he talk about that on his show Mad Money, SELL SELL SELL.... Who knows what agenda these guys are on and they should be kicked out on the street dot com.
Cel Sci Corp. Releases Letter to ShareHolders Oct 5 2009
CEO Interview explaining about the company and their goals
Cel Sci Press Releases
More Information and Research on Cel-Sci Corp
|
|